

Supplemental Table 2: Patient Outcomes for patients surviving severe COVID-19

Outcome Measures	Baseline Mean ± SD (n)			3-month Mean ± SD (n)			Paired t-test	Independent t-test
	Cohort	In-person	Telehealth	Cohort	In-person	Telehealth		
6 MWD, meters	224 ± 142 (32)	246 ± 142 (22)	154 ± 121 (10)	326 ± 143 (29)	362 ± 131 (20)	241 ± 137 (9)	t = 5.97, p < 0.0001	t = 1.34, p = 0.19
2-min step test	68.3 ± 23 (10)			94.3 ± 28.6 (9)			t = 2.17, p = 0.046	
MRC-ss	52.4 ± 6.3 (31)	52.9 ± 5.8 (22)	51.1 ± 7.7 (9)	57.8 ± 3.3 (26)	58 ± 2.9	57.2 ± 5.2 (5)	t = 3.45, p < 0.0001	t = 0.03, p = 0.97
Handgrip strength								
Right	25.9 ± 8.9 (30)	26.3 ± 9.1 (22)	25.1 ± 9.1 (8)	29.8 ± 9.1 (26)	29.3 ± 9.1 (20)	32.3 ± 9.3 (5)	t = 3.01, p = 0.004	t = 1.56, p = 0.144
Left	25.5 ± 9.4 (30)	26 ± 10.5 (22)	23.3 ± 10.9 (8)	30.1 ± 9.6 (26)	29.5 ± 12 (20)	31.1 ± 8.2 (5)	t = 3.45, p = 0.002	t = 1.63, p = 0.131
Chair stand test, sec	15.7 ± 7.6 (28)	16.0 ± 8.4 (20)	13 ± 3.8 (8)	11.2 ± 4.5 (28)	10.6 ± 5.0 (20)	11.7 ± 3.1 (8)	t = 3.56, p = 0.001	t = 0.57, p = 0.571
4m-gait-velo, m/sec	0.81 ± 0.3 (32)	0.87 ± 0.3 (22)	0.62 ± 0.4 (10)	1.0 ± 0.27 (29)	1.07 ± 0.29 (20)	0.98 ± 0.28 (9)	t = 4.43, p < 0.0001	t = 2.10, p = 0.046
SPPB, 0-12	7.8 ± 3.6 (32)	8.1 ± 3.3 (22)	6.4 ± 4.0 (10)	10.1 ± 2.5 (29)	10.6 ± 1.9 (20)	8.8 ± 3.4 (9)	t = 5.01, p < 0.0001	t = 0.04, p = 0.971
TUG, sec	14.2 ± 8.5 (27)	14.6 ± 9.1 (22)	11.6 ± 3.7 (5)	11.1 ± 4.95 (26)	11.2 ± 4.7 (20)	13 ± 6.1 (5)	t = 2.73, p = 0.012	t = 1.06, p = 0.304
QOL, VAS, 0-100	72 ± 16.1 (32)	74 ± 16.9 (22)	64 ± 14.1 (10)	83.4 ± 16.6 (29)	87 ± 13 (20)	74.5 ± 21 (9)	t = 3.85, p = 0.0005	t = 1.05, p = 0.306
HADS-anxiety	6.8 ± 5.3 (30)	5.8 ± 4.7 (20)	9 ± 6.1 (10)	6.1 ± 5.9 (28)	5.2 ± 5.9 (19)	8 ± 6.1 (9)	t = 1.12, p = 0.270	t = 0.96, p = 0.349
HADS-depression	6.3 ± 4.5 (30)	6.4 ± 4.7 (20)	6.4 ± 4.3 (10)	4.9 ± 3.9 (28)	4.5 ± 3.8 (19)	5.8 ± 4.5 (9)	t = 2.22, p = 0.035	t = 0.59, p = 0.562
IES-R, 0-88	27.2 ± 23 (28)	26 ± 21.2 (19)	29 ± 27.6 (10)	20.8 ± 22 (27)	19.8 ± 20.4 (18)	25.5 ± 26 (9)	t = 2.99, p = 0.006	t = 0.16, p = 0.874
MOCA, % ⁱⁱⁱ	76 ± 24 (28)	76 ± 22 (20)	73 ± 28 (10)	83.6 ± 19 (27)	86.3 ± 9.6 (18)	78.2 ± 30.2 (9)	t = 2.52, p = 0.018	t = 0.27, p = 0.793
MRC-dyspnea scale	3.5 ± 1.0 (32)	3.3 ± 0.98 (22)	3.8 ± 0.93 (10)	2.2 ± 1.1 (29)	2 ± 1.1 (20)	2.5 ± 0.88 (9)	t = 7.78, p < 0.0001	t = 0.13, p = 0.896

6 MWD = six-minute walk distance; MRC-ss = medical research council-sum score; TUG = time-up and go-test; QOL = quality of life; VAS= visual analog scale;

HADS = hospital anxiety and depression scale; IES-R = Impact of Events Scale-Revised; MOCA = Montreal Cognitive Assessment;

ⁱ Paired t-test comparing baseline to 3-months for the cohort (in-person and telehealth aggregated into one group) with exception of the 2-minute step test comparing baseline to 3-months for telehealth only.

ⁱⁱ Independent t-test comparing outcomes at the 3-monthfollow-up assessment comparing in-person vs telehealth group

ⁱⁱⁱ Data are presented as a percentage of MOCA full (0-30) or MOCA-blind (0-22)